

PRESS RELEASE
18.11.2022

PROGEN to supply PerkinElmer AAV2 capsid specific antibody for AlphaLISA® immunoassay kit

Heidelberg, November 18, 2022 – PROGEN Biotechnik GmbH, a manufacturer of an exclusive portfolio of adeno-associated (AAV) antibodies and AAV gene therapy tools, announces a supply agreement to provide one of its antibody products to PerkinElmer, a global leader committed to innovating for a healthier world. PROGEN's AAV2 capsid specific antibody will be used in PerkinElmer's AlphaLISA® Immunoassay AAV2 Capsid Detection Kit. PROGEN supports the gene therapy community in its mission to develop advanced therapy solutions based on safe AAV vectors.

Increasing interest in AAV vectors for gene therapy development demands a dependable and reproducible quantification of accurate recombinant AAV titers to ensure a reliable and standardized gene transfer. A major challenge is the use of orthogonal methods for comprehensive characterization of AAV gene therapies. PROGEN's AAV2 ELISA is considered the gold standard in AAV2 capsid titer determination, enjoying the trust of the AAV gene therapy community worldwide.

PerkinElmer's AlphaLISA immunoassay AAV2 Capsid Detection Kit offers a bead-based luminescent amplification no-wash assay that complements available orthogonal methods for quantitative determination of AAV2 capsids, including PROGEN's AAV2 ELISAs. As part of the supply agreement, PROGEN will provide its serotype-specific, recombinant AAV2 capsid antibody from its comprehensive serotype-specific AAV analysis portfolio. PROGEN's openness to support orthogonal methods in the AAV gene therapy field follows its commitment to support the sector in improving and expanding safe and reliable treatment for their patients.

CEO Katja Betts welcomes the arrangement: "PROGEN is always looking to advance AAV development and manufacturing to accelerate the transfer to clinical development. We are excited to have our AAV2 capsid antibody as part of PerkinElmer's innovative AlphaLISA kit for serotypic AAV titer determination. This agreement underscores PROGEN's key position in AAV vector quality analysis."

PROGEN's AAV capsid detection antibodies are established tools in vector manufacturing and quality control, including automated use. In combination with the company's AAV particle antibodies they can be integrated to monitor every step of the process, controlling identity, yield, potency, purity and integrity along the way to ensure the quality and safety of the vector preparation. The company aims to further expand its leading role in the AAV gene therapy market and welcomes enquiries for further supply agreements, collaborations and partnerships.

About PROGEN

Starting out in 1983 as pioneers in antibody manufacturing, PROGEN has since become a globally operating biotech company that serves the life science and pharma sectors. We believe that our research antibodies and test kits are more than commodities but enabling tools for the advancement of research and development in academia and industry alike. Our goal is to provide well-established and reliable products that fuel the biopharmaceutical and diagnostic progress along the complete value chain – from basic research, to manufacturing and quality control. .

The PROGEN team consists of life science and adeno-associated virus (AAV) experts and is partnered with specialists within the field of gene therapy and the life sciences worldwide. We are more than just a manufacturer of antibodies, AAV gene therapy tools, density gradient media and phage display technologies. We strive to understand what scientists need, so we can create solutions and ultimately deliver high quality antibody and exclusive AAV products, which solve research challenges within academia, biotech and pharma. It is in our corporate DNA to ensure support throughout the whole process – from inquiry to application as a trusted and reliable partner. Based in Heidelberg, PROGEN has been a 100% subsidiary of R-Biopharm AG since 2012.

Media contact

Caroline Odenwald
Head of Marketing
Phone: +49 6221 8278-0
E-Mail: odenwald@progen.com

Image & caption

----- ©PROGEN -----

PROGEN is an established provider of AAV antibodies and ELISAs for vector analysis in gene therapy research and development."

